Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people ...
BEIJING, Sept. 18, 2025 /PRNewswire/ -- Beijing QL Biopharmaceutical Co., Ltd. (hereafter "QL Biopharm" or the "company") announced today at the European Association for the Study of Diabetes (EASD) ...
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 ...
Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...
Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...
Amgen, announced full results from part 1 of the phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results